You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 6,723,713

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,723,713

Title:	Use of mometasone furoate for treating upper airway diseases
Abstract:	The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
Inventor(s):	Sequeira; Joel A. (Scotch Plains, NJ), Cuss; Francis M. (Basking Ridge, NJ), Nolop; Keith B. (Millburn, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Nagabhushan; Nagamani (Parsippany, NJ), Patrick; James E. (Belle Meade, NJ), Cayen; Mitchell (Bedminster, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	10/426,329
Patent Claims:	1. A method of treating allergic rhinitis comprising administering once daily nasal passages 200 micrograms of mometasone furoate. 2. The method of claim 1, wherein the mometasone furoate is administered as anhydrous mometasone furoate. 3. The method of claim 1, wherein the mometasone furoate is administered as mometasone furoate monohydrate. 4. The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension. 5. The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension of mometasone furoate monohydrate. 6. The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension of anhydrous mometasone furoate. 7. The method of claim 1, wherein there are administered 200 micrograms of mometasone furoate by applying twice to each nostril about 50 micrograms of mometasone furoate. 8. A method of treating a disease comprising allergic rhinitis, comprising administering once daily to nasal passages an aqueous nasal spray comprising mometasone furoate monohydrate, in an amount providing about 100 micrograms of mometasone furoate to each nostril. 9. The method of claim 8, wherein there are administered 200 micrograms of mometasone furoate by applying twice to each nostril about 50 micrograms of mometasone furoate. 10. A method of treating a disease comprising allergic rhinitis, comprising administering once daily to nasal passages an aqueous nasal spray comprising mometasone furoate monohydrate, in an amount providing about 50 micrograms of mometasone furoate to each nostril.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.